Vertex Pharmaceuticals

VRTXintermediary

Vertex Pharmaceuticals dominates the cystic fibrosis market with Trikafta and is expanding into gene editing (Casgevy for sickle cell), non-opioid pain (suzetrigine), and kidney disease. Its CF franchise generates massive cash flow to fund pipeline diversification.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($11.2B)

Datos estáticos (cargando finanzas en tiempo real…)

Cystic Fibrosis (Trikafta) (78%)

Gene Therapy (Casgevy) (8%)

Other Products & Collaborations (14%)

Composición de segmentos y clientes principales

Detalles del producto

Trikafta / Kaftrio65%

Triple-combination CFTR modulator for cystic fibrosis — standard of care

Casgevy (exa-cel)8%

CRISPR-based gene therapy for sickle cell disease and beta-thalassemia

Pain Pipeline (VX-548, suzetrigine)10%

Non-opioid NaV1.8 pain inhibitor for acute and neuropathic pain

Relaciones en la Cadena de Suministro

Competidores

Eli Lilly and Company

Pain therapeutics pipeline

Impacto: Competing in non-opioid pain

Regeneron Pharmaceuticals

Gene editing and rare disease

Impacto: Competing in genetic medicine

Pfizer Inc.

Gene therapy and rare disease

Impacto: Limited overlap

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Vertex Pharmaceuticals impulsado por IA.

Información de la Empresa

Sede Central

Boston, Massachusetts, USA

Fundación

1989

Empleados

10,400+

Sitio Web

vrtx.com

Estado del sector — 제약 / 바이오

Noticias del sector